Shahneen Sandhu
Peter MacCallum Cancer Research · Peter MacCallum Cancer Centre, Australia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shahneen Sandhu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:36 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05425862 · Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerPeter MacCallum Cancer Centre, Australia · terminated · Metastatic Castration Resistant Prostate Cancer (mCRPC) · principal investigator
- Ph2NCT05150236 · EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCAustralian and New Zealand Urogenital and Prostate Cancer Trials Group · unknown · Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms · study chair
- Ph1/Ph2NCT04261855 · Targeted Therapy and Avelumab in Merkel Cell CarcinomaMelanoma and Skin Cancer Trials Limited · active not recruiting · Metastatic Merkel Cell Carcinoma · study chair
- Ph1NCT03874884 · 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate CancerPeter MacCallum Cancer Centre, Australia · active not recruiting · Metastatic Castration Resistant Prostate Cancer (mCRPC) · principal investigator
- Ph1/Ph2NCT03658447 · PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)Peter MacCallum Cancer Centre, Australia · completed · Metastatic Castration Resistant Prostate Cancer · principal investigator
- Ph1/Ph2NCT03161756 · Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaMelanoma and Skin Cancer Trials Limited · unknown · Melanoma Stage Iv, Melanoma Stage Iii, Melanoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:36 UTC. The ranking covers the 200 most relevant of 111 PubMed records, and a shared surname and initials can bring in a namesake. All 111 on PubMed
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 20201,923 citationsRCR 83.2
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.N Engl J Med · 20151,852 citationsRCR 53.5
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.N Engl J Med · 20181,569 citationsRCR 53.2
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med · 20191,331 citationsRCR 51.5
- 966 citationsRCR 59.1
- [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.Lancet Oncol · 2018943 citationsRCR 38.7
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.Lancet Oncol · 2018815 citationsRCR 26.8
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 2020675 citationsRCR 25.8
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.N Engl J Med · 2025540 citationsRCR 120.6
- 522 citationsRCR 20.5